BioMotiv (@biomotiv) 's Twitter Profile
BioMotiv

@biomotiv

Accelerating breakthrough discoveries into medicines, affiliated with The #HarringtonProject. #impinv #drugdevelopment #biotech #CLE

ID: 928009319848824834

linkhttp://www.biomotiv.com calendar_today07-11-2017 21:20:38

461 Tweet

298 Followers

354 Following

BioMotiv (@biomotiv) 's Twitter Profile Photo

#SapVax is developing a novel cancer vaccine platform that has the potential to be used in combination with other #immunooncology drugs, including #checkpointinhibitors and #neoantigens. Learn more: sapvaxllc.com Margaret Brimble

BioMotiv (@biomotiv) 's Twitter Profile Photo

There are approximately 100,000 patients with #retinitispigmentosa living in the US, but there is no cure for the disease. #OptiKira is developing compounds that would slow progression of the disease: OptiKira.com Foundation Fighting Blindness @arixbioscience Charles River Labs

BioMotiv (@biomotiv) 's Twitter Profile Photo

BioMotiv and Atomwise announced a strategic collaboration today to integrate AI technology, drug development expertise and an ecosystem of partners for the commercialization of promising early-stage research: bit.ly/35QbSup

BioMotiv and Atomwise announced a strategic collaboration today to integrate AI technology, drug development expertise and an ecosystem of partners for the commercialization of promising early-stage research: bit.ly/35QbSup
BioMotiv (@biomotiv) 's Twitter Profile Photo

One of our portfolio companies, Aro Biotherapeutics recently announced a licensing and collaboration agreement with a top tier pharmaceutical company, Ionis Pharmaceuticals – the leader in RNA based therapeutics. Read more here: bit.ly/2teGvMS

BioMotiv (@biomotiv) 's Twitter Profile Photo

BioMotiv, associated with #TheHarringtonProject, and Bristol-Myers Squibb launch their first #biotech after the announcement of their partnership, Anteros Pharmaceuticals, focused on developing new class of drugs for #fibrotic and #inflammatorydiseases. bit.ly/2SkVVrc

BioMotiv, associated with #TheHarringtonProject, and Bristol-Myers Squibb launch their first #biotech after the announcement of their partnership, Anteros Pharmaceuticals, focused on developing new class of drugs for #fibrotic and #inflammatorydiseases. bit.ly/2SkVVrc
BioMotiv (@biomotiv) 's Twitter Profile Photo

#KoutifTherapeutics, one of our portfolio companies, received $250,000 in grant funding from the Crohn's & Colitis Foundation to support the development of novel small molecule therapeutics for the treatment of #IBD and #Crohnsdisease. Read more here: bit.ly/37596lt

Cleveland Foundation (@clevefoundation) 's Twitter Profile Photo

Help #CLE’s most vulnerable by contributing to the Greater #Cleveland #COVID19 Rapid Response Fund today: bit.ly/CLEgives. #CLEresponds #COVID19OhioReady

University Hospitals (@uhhospitals) 's Twitter Profile Photo

A COVID-19 (coronavirus) vaccine is in development - but what’s the process and when will it be available? Dr. Robert Salata, Program Director, UH Roe Green Center for Travel Medicine & Global Health, explains. #COVID19 #coronavirus

Athersys Inc (@athersys) 's Twitter Profile Photo

#Athersys CEO Gil Van Bokkelen was on Fox News on @AmericasNewsroom sharing the Athersys story about our #COVID19 induced #ARDS program using #MultiStem cell therapy. $ATHX foxnews.com/health/cell-th…

Baiju R. Shah (@baiju_r_shah) 's Twitter Profile Photo

Advising a #COVID19 research initiative for #socialimpact. Your #COVID19 experience as a patient or caregiver can make a difference. Join the Study Covid Project (studycovid.org) to help leaders make smarter decisions. FasterCures MetroHealth Diabetes Daily

BioMotiv (@biomotiv) 's Twitter Profile Photo

We are excited to announce The Harrington Discovery Institute at University Hospitals launched a five-part initiative to accelerate near-term therapies for treating Coronavirus and future pandemic threats. Learn more here: bit.ly/3e1MzuO

BioMotiv (@biomotiv) 's Twitter Profile Photo

Excited to announce our investment in @AmphistaTherapeutics alongside Advent Life Sciences. Amphista Therapeutics is a biopharmaceutical company with a novel targeted protein degradation platform. Read more here: bit.ly/2V88FTM

Athersys Inc (@athersys) 's Twitter Profile Photo

FDA authorizes #Athersys to initiate a pivotal clinical trial evaluating #MultiStem Cell Therapy in patients with #COVID19 induced #ARDS. businesswire.com/news/home/2020…

BioMotiv (@biomotiv) 's Twitter Profile Photo

Exciting news from Cleveland-based SecondBreath on their FDA approval to produce ventilators for coronavirus patients. Inspiring to see CLE-based companies innovate and step-up during this crisis. bit.ly/3cqr3ho #Cleveland #COVID19 #CLEresponds

Greater Cleveland Partnership (@greatercle) 's Twitter Profile Photo

We are seeing more retooling in our manufacturing sector to combat COVID-19. Thank you, U.S. Cotton #InThisTogetherCLE #ChamberStrong #Cleveland company approved to make swabs for coronavirus testing cleveland.com/open/2020/04/c…

BioMotiv (@biomotiv) 's Twitter Profile Photo

Congratulations to the Amphista Therapeutics team on their recent appointment of Dr. Ian Churcher, an internationally recognized leader in the field of targeted protein degradation, as Chief Scientific Officer. Read more here: bit.ly/3e8W2PU #CSO #cancertherapeutics

Michelle Jarboe (@mjarboe) 's Twitter Profile Photo

Tuned in to a virtual discussion this afternoon with Commerce Secretary Wilbur Ross, who praised the resilience of #CLE-area businesses but sounded the alarm on the city’s poor response rate to the census. ⁦Follow GCP @GreaterCLE⁩ crainscleveland.com/manufacturing/…